

1  
2  
3  
4  
5  
6  
7 SHAUN L.W. SAMUELS,  
8 Plaintiff,  
9 v.  
10 TRIVASCULAR CORPORATION, et al.,  
11 Defendants.

Case No. 13-cv-02261-EMC

**CLAIM CONSTRUCTION ORDER**

Docket Nos. 81-82, 84

12  
13 Plaintiff Shaun L.W. Samuels is the owner of the '575 patent which concerns an inflatable  
14 stent. Dr. Samuels has accused Defendant TriVascular Corporation and several individuals  
15 affiliated with the company of patent infringement (collectively, "TriVascular"). Currently  
16 pending before the Court are the parties' competing briefs regarding claim construction of the '575  
17 patent.

18 **I. FACTUAL & PROCEDURAL BACKGROUND**

19 As noted above, the '575 patent concerns an inflatable stent. For the most part, a  
20 representative claim from the patent is claim 1. Claim 1 reads as follows:

21  
22 1. An inflatable intraluminal stent adapted to be secured to the  
interior of a tubular structure within the human body comprising:  
23  
24 a) **an inflatable and deflatable cuff of generally hollow**  
**cylindrical continuation** having a collapsible lumen, an inner  
surface, an inlet, an outlet and a friction enhancing outer surface,  
said friction-enhancing outer surface featuring **inflatable**  
**protrusion(s) including at least one circumferential ridge**  
**disposed about the inflatable cuff, said friction-enhancing outer**  
**surface engaging the interior of the tubular structure without**  
**penetration to prevent the cuff from moving** in a longitudinal  
direction with respect to the tubular structure when said cuff is in a  
fully inflated condition;

25  
26  
27  
28

b) means for injecting an inflation material into said cuff to inflate it; and

- c) a valve integral with the inflatable cuff for permitting entry of the inflation material from the means for injecting and thereafter sealing said cuff to prevent deflation.

‘575 patent, claim 1 (emphasis added). Terms to be construed include those bolded above.

## II. DISCUSSION

#### A. Legal Standard

Claim construction is a question of law to be determined by the Court. *See Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 979 (Fed. Cir. 1995) (“hold[ing] that in a case tried to a jury, the court has the power and obligation to construe as a matter of law the meaning of language used in the patent claim”). “The purpose of claim construction is to ‘determin[e] the meaning and scope of the patent claims asserted to be infringed.’” *O2 Micro Int'l Ltd. v. Beyond Innovation Tech. Co.*, 521 F.3d 1351, 1360 (Fed. Cir. 2008).

Words of a claim are generally given their ordinary and customary meaning, which is the meaning a term would have to a person of ordinary skill in the art after reviewing the intrinsic record at the time of the invention. “In some cases, the ordinary meaning of claim language . . . may be readily apparent even to lay judges, and claim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.” However, in many cases, the meaning of a claim term as understood by persons of skill in the art is not readily apparent.

*Id.*

Because the meaning of a claim term as understood by persons of skill in the art is often not immediately apparent, and because patentees frequently use terms idiosyncratically, the court looks to “those sources available to the public that show what a person of skill in the art would have understood disputed claim language to mean.” Those sources include “the words of the claims themselves, the remainder of the specification, the prosecution history, and extrinsic evidence concerning relevant scientific principles, the meaning of technical terms, and the state of the art.”

*Phillips v. AWH Corp.*, 415 F.3d 1303, 1314 (Fed. Cir. 2005). As a general matter, extrinsic evidence such as dictionaries and expert testimony is considered less reliable than intrinsic evidence (*i.e.*, the patent and its prosecution history). *See id.* at 1317-19 (noting that “extrinsic evidence may be useful to the court, but it is unlikely to result in a reliable interpretation of patent

1 claim scope unless considered in the context of the intrinsic evidence”).

2 Generally, embodiments from the specification should not be imported into the claims as  
 3 limitations. *See Toshiba Corp. v. Imation Corp.*, 681 F.3d 1358, 1369 (Fed. Cir. 2012) (“We do  
 4 not read limitations from the specification into claims.”). “There are only two exceptions to this  
 5 general rule: (1) when a patentee sets out a definition and acts as his own lexicographer, or (2)  
 6 when the patentee disavows the full scope of the claim term either in the specification or during  
 7 prosecution.” *Thorner v. Sony Computer Entm't Am. LLC*, 669 F.3d 1362, 1365 (Fed. Cir. 2012).

8 B. “means for injecting an inflation material into said cuff to inflate it” and “means for  
 9 inflating the cuff with inflation material”

11 Dr. Samuels's Proposed 12 Construction	11 TriVascular's Proposed 12 Construction	11 Court's Construction
13 “means for injecting an inflation material into said cuff to inflate it”		
14 <b>Function:</b> The function is 15 injecting an inflation material 16 into said cuff to inflate it.  17 <b>Structure:</b> The corresponding 18 structure is an inflation device, 19 such as the kind of syringe 20 shown in Figs. 1 and 9a-9c (71, 117) and inflation tubing 21 (61, 115).  22 23 24 25 26 27 28	14 <b>Function:</b> The same.  17 <b>Structure:</b> The corresponding structure is an inflation syringe of the kind shown in Figs. 1 and 9a-9c (71, 117) containing an inflation material; inflation tubing (61, 115) with a mating end (63) that opens a valve by separating opposing leaflets (51, 53) that are in an inflation port (39, 123) to inflate the cuff.  3	14 <b>Function:</b> The function is injecting an inflation material into said cuff to inflate it.  17 <b>Structure:</b> The corresponding structure is an inflation syringe of the kind shown in Figs. 1 and 9a-9c (71, 117), inflation tubing (61, 115), and a valve.

<b>“means for inflating the cuff with inflation material”</b>		
<p>3      <b>Function:</b> The function is 4      inflating the cuff with inflation 5      material.</p> <p>6      <b>Structure:</b> The corresponding 7      structure is an inflation device, 8      such as the kind of syringe 9      shown in Figs. 1 and 9a-9c 10     (71, 117) and inflation tubing 11     (61, 115).</p>	<p>3      <b>Function:</b> The same.</p> <p>6      <b>Structure:</b> The corresponding 7      structure is an inflation 8      syringe of the kind shown in 9      Figs. 1 and 9a-9c (71, 117) 10     containing an inflation 11     material; inflation tubing (61, 12     115) with a mating end (63) 13     that opens a valve by 14     separating opposing leaflets 15     (51, 53) that are in an inflation 16     port (39, 123) to inflate the 17     cuff with the inflation 18     material.</p>	<p>3      <b>Function:</b> The function is 4      inflating the cuff with inflation 5      material.</p> <p>6      <b>Structure:</b> The corresponding 7      structure is an inflation 8      syringe of the kind shown in 9      Figs. 1 and 9a-9c (71, 117), 10     inflation tubing (61, 115), and 11     a valve.</p>

19     The first term (“means for injecting an inflation material into said cuff to inflate it”) can be  
20     found in, *e.g.*, claim 1(b). The second term (“means for inflating the cuff with inflation material”)  
21     can be found in, *e.g.*, claim in 14(c).

22     Both parties agree that the two terms should be considered together. Both parties also  
23     agree that the above terms are means-plus-function limitations. Means-plus-function limitations  
24     were, at the time, governed by paragraph 6 of 35 U.S.C. § 112, which provided as follows:

26     An element in a claim for a combination may be expressed as a  
27     means or step for performing a specified function without the recital  
28     of structure, material, or acts in support thereof, and such claim shall  
   be construed to cover the corresponding structure, material, or acts  
   described in the specification and equivalents thereof.

1 35 U.S.C. § 112 (1999).

2  
3 In enacting this provision, Congress struck a balance in allowing  
4 patentees to express a claim limitation by reciting a function to be  
5 performed rather than by reciting structure for performing that  
6 function, while placing specific constraints on how such a limitation  
is to be construed, namely, by restricting the scope of coverage to  
only the structure, materials, or acts described in the specification as  
corresponding to the claimed function and equivalents thereof.

7 *Williamson v. Citrix Online, LLC*, 792 F.3d 1339, 1347 (Fed. Cir. 2015) (en banc).

8 Here, the parties do not have a dispute as to what the claimed functions of the means-plus-  
9 function elements are – *i.e.*, injecting an inflation material into the cuff to inflate it and inflating  
10 the cuff with inflation material. (As indicated by the above, the functions for the two elements are  
11 essentially the same.) Rather, the parties dispute what the corresponding structure for each  
12 function is. Dr. Samuels argues that, in each case, the structure that performs the function is  
13 simply a syringe and inflation tubing. In response, TriVascular contends that the structure is not  
14 just a syringe and inflation tubing but also includes a valve.<sup>1</sup>

15 In his papers, Dr. Samuels contends that a valve should not be part of the structure because  
16 there is a *different* claim element (*e.g.*, claim 1(c) instead of claim 1(b)) that addresses a valve.  
17 *See* Op. Br. at 9. But as TriVascular argues in its papers, one structure can perform multiple  
18 functions, not just one – *i.e.*, nothing bars a valve from performing the function of “permitting  
19 entry of the inflation material from the means for injecting and thereafter sealing said cuff to  
20 prevent deflation” (claim 1(c)) and *also* performing the function of inflating the cuff with inflation  
21 material (claim 1(b)). This makes practical sense. In addition, TriVascular has support for its  
22 position from *Intellectual Property Development, Inc. v. UA-Columbia Cablevision of*  
23 *Westchester, Inc.*, 336 F.3d 1308 (Fed. Cir. 2003) (hereinafter *IPD*).

24 In *IPD*, one element in the claim at issue was “*light beam demodulation means* at said  
25 reception position responsive to said *photo-sensitive detector means* to convert said light beam

26  
27 

---

<sup>1</sup> TriVascular’s construction also refers to, *e.g.*, the mating end of inflation tubing, leaflets,  
28 an inflation port, and inflation material, *see* Resp. Br. at 5, but at the core of its argument is the  
valve.

1 into demodulated high frequency carrier radio wave signals modulated with video broadcast  
2 signals.”” *Id.* at 1312 (emphasis added). According to the district court,

3  
4 since the claim language requires that the “photo-sensitive detector  
5 means” and the “light beam demodulation means” be “responsive  
6 to” each other, they could not, as urged by [the plaintiff], be  
contained in the same structure, i.e., the photo-sensitive detector.  
Otherwise, according to the court, the words ‘responsive to’ would  
be read out of the claim.

7 *Id.* at 1318. The Federal Circuit disagreed with the district court, stating as follows: “Contrary to  
8 [the defendant’s] argument, we see no reason why, as a matter of law, one claim limitation may  
9 not be responsive to another merely because they are located in the same physical structure.” *Id.*  
10 at 1320 n.9. At least one court has expressly cited *IPD* for the proposition that “multiple claimed  
11 functions can share the same corresponding structure or structures.” *Morvil Tech. v. Medtronic*  
12 *Ablation Frontiers*, No. 10-CV-2088 BEN (BGS), 2012 U.S. Dist. LEXIS 113029, at \*51 (S.D.  
13 Cal. Aug. 10, 2012).

14 The instant case, of course, is somewhat different from *IPD*. In *IPD*, the Federal Circuit  
15 was confronted with *two* means-plus-function elements (the light beam demodulation means and  
16 the photo-sensitive detector means), and that is not the case here. But the underlying point of *IPD*  
17 still has application in the case at bar – *i.e.*, a valve is not automatically foreclosed from being  
18 structure for purposes of claim 1(b) just because it also shows up in claim 1(c).

19 Dr. Samuels protests, however, that just because a valve is part of the inflating process  
20 does not mean that the valve does the inflating itself; what does the actual inflating is the syringe  
21 and inflation tubing. Admittedly, Dr. Samuels has some support for his position from the ‘575  
22 specification, which states, *inter alia*, as follows: “Referring back to FIG. 1, cuff 17 is inflated by  
23 way of an inflation syringe 71 with an inflation material 73.” ‘575 patent, col. 4:33-34.

24 But, notably, other parts of the ‘575 specification indicate that a valve is not just a part of  
25 the inflation process; rather, it is a *necessary element* to accomplish the inflation. *Compare*  
26 *Welker Bearing Co. v. PHD, Inc.*, 550 F.3d 1090, 1097 (Fed. Cir. 2008) (emphasis added) (noting  
27 that a ““court may not import . . . structural limitations from the written description that are  
28 unnecessary to perform the claimed function””) (emphasis added); *see also Wenger Mfg., Inc. v.*

1        *Coating Machinery Sys., Inc.*, 239 F.3d 1225, 1233 (Fed. Cir. 2001) (stating that “the court  
2        improperly restricted ‘air circulation means’ limitation to structure that was disclosed in the  
3        preferred embodiment, but was not necessary to perform the recited function of circulating air”).

4        •        “The cuff **17** is inflated and deflated *by means of a valve*, indicated generally at **37** in  
5        FIGS. **4a** and **4b**, which is integral with inflation port **39** of cuff **17**.” ‘575 patent, col. 4:8-  
6        10 (emphasis added).

7        •        “As shown in FIG. **4a**, when inflation tubing **61** is in an engaged configuration *with valve*  
8        **37**, mating end **63** separates opposing leaflets **51** and **53** so that cuff **17** may be inflated or  
9        deflated.” ‘575 patent, col. 4:17-20 (emphasis added).

10        That a valve is a necessary element to accomplish inflation is underscored by the fact that  
11        the inflation material can be “a saline-based fluid or a material that contains a photo-activated or  
12        heat-activated hardening agent or any hardening agent that hardens over time.” ‘575 patent, col.  
13        4:35-37. In either case, the valve is necessary to accomplish inflation (and not just prevent  
14        deflation after inflation is achieved, *see Part II.D, infra*) or the material will, in effect “leak out.”  
15        This is true even where the material contains a hardening agent because hardening is a process that  
16        takes at least some time.

17        In response, Dr. Samuels suggests that a valve is not necessary based on the language of  
18        claims 9 and 19. Claim 9 covers “[t]he inflatable intraluminal stent of claim **1** wherein the valve is  
19        of a breakaway design to permit separation *from the means for injecting*.” ‘575 patent, claim 9  
20        (emphasis added). Claim 19 covers “[t]he apparatus of claim **14** wherein the valve is of a  
21        breakaway design to permit separation *from the means for inflating*.” ‘575 patent, claim 19  
22        (emphasis added); *see also* ‘575 patent, claim 13 (addressing “[t]he inflatable intraluminal stent of  
23        claim **1** wherein the means for injecting an inflation material into said inflatable cuff to inflate it  
24        includes an inflation syringe and inflation tubing”). But TriVascular correctly notes that the  
25        Federal Circuit has “long held that a patentee cannot rely on claim differentiation to broaden a  
26        means-plus-function limitation beyond those structures specifically disclosed in the specification.”  
27        *Saffran v. Johnson & Johnson*, 712 F.3d 549, 563 (Fed. Cir. 2013); *see also Nomos Corp. v.*  
28        *BrainLAB USA, Inc.*, 357 F.3d 1364, 1368 (Fed. Cir. 2004) (noting that “our interpretation of the

1 corresponding structure comes from the written description, not from [a] dependent claim”; adding  
 2 that “claim differentiation, which is a ‘guide, not a rigid rule,’ does not override the requirements  
 3 of § 112, ¶ 6 when the ‘claim will bear only one interpretation’”; and thus concluding that the  
 4 means for “generating at least one ultrasound image” includes both an ultrasound probe and a  
 5 fixation device, not just the probe alone).

6 Accordingly, the corresponding structure for the two means-plus-function limitations  
 7 identified above is an inflation syringe of the kind shown in Figs. 1 and 9a-9c (71, 117), inflation  
 8 tubing (61, 115), *and* a valve. Section 112 ¶ 6, of course, also provides coverage for equivalents  
 9 thereof.

10 C. “inflatable protrusion(s) including at least one circumferential ridge disposed about the  
 11 inflatable cuff”

12	13 <b>Dr. Samuels’s Proposed</b> <b>Construction</b>	14 <b>TriVascular’s Proposed</b> <b>Construction</b>	15 <b>Court’s Construction</b>
16	17 A portion or portions of the outer surface of the cuff that protrude outward of the cuff upon inflation.	18 A portion or portions of the outer surface of the inflatable cuff that are themselves inflatable by being filled with fluid that protrude outward from the flat portions of the outer surface of the inflated cuff, including at least one ridge that goes around the cuff.	19 A portion or portions of the outer surface of the inflatable cuff that protrude outward of the cuff and that are themselves inflatable, <i>i.e.</i> , expandable by being filled with fluid, including at least one ridge that goes around the cuff.

25  
 26 The term can be found in, *e.g.*, claim 1(a).

27 As argued by TriVascular, the main dispute regarding the term seems to be whether the  
 28 protrusions, which are themselves inflatable, must be inflatable by being filled with fluid. In his

1 reply brief, Dr. Samuels failed to address this point. *See* Reply at 6. That being the case, the  
2 Court adopts the limitation advocated for by TriVascular (*i.e.*, as unopposed).

3 Moreover, there is a substantive basis supporting the “fluid” limitation. Although the bulk  
4 of the ‘575 patent, including the specification, does not make any mention of the protrusions being  
5 filled with fluid, the specification does state: “As illustrated in FIG. 2, circumferential ridges **25**  
6 are in fluid communication with the inflatable chamber **27** of cuff **17.”** ‘575 patent, col. 3:54-56.  
7 *Cf. ICU Med., Inc. v. Alaris Med. Sys.*, 558 F.3d 1368, 1374-75 (Fed. Cir. 2009) (agreeing with  
8 district court’s construction of “spike” to mean ““an elongated structure having a pointed tip for  
9 piercing the seal, which tip may be sharp or slightly rounded”” because it is “appropriate ‘to rely  
10 heavily on the written description for guidance as to the meaning of the claims’” and “the  
11 specification ‘repeatedly and uniformly describes the spike as appointed instrument for the  
12 purpose of piercing a seal inside the valve’”).<sup>2</sup>

13 Furthermore, as TriVascular argues, the “fluid” limitation is supported based on what Dr.  
14 Samuels told the PTAB during the inter partes review (“IPR”) proceedings. In this regard,  
15 TriVascular makes a prosecution disclaimer-type argument. That doctrine ““preclud[es] patentees  
16 from recapturing through claim interpretation specific meanings disclaimed during prosecution.””  
17 *TomTom, Inc. v. Adolph*, 790 F.3d 1315, 1325 (Fed. Cir. 2015). While the doctrine does not apply

---

19 <sup>2</sup> Notably, the *ICU* court acknowledged that “we should not import limitations from the  
20 specification into the claims.” *ICU*, 558 F.3d at 1375. The court added, however, that

21 “the line between construing terms and importing limitations can be  
22 discerned with reasonable certainty and predictability if the court’s  
23 focus remains on understanding how a person of ordinary skill in the  
24 art would understand the claim terms.” Indeed, the court should  
25 focus on how such a person would understand the claim term “after  
26 reading the entire patent.” *The specification never suggests that the  
27 spike can be anything other than pointed.* As the district court  
noted, (1) each figure depicts the spike as elongated and pointed; (2)  
in each figure depicting an activated valve, the spike pierces the  
seal; and (3) the patents neither describe piercing as optional nor  
describe any non-piercing item as a spike. Moreover, *ICU* offers no  
support from any intrinsic or extrinsic source in support of its claim  
that the ordinary meaning of spike would include a non-pointed  
structure such as a tube or a straw.

28 *Id.* (emphasis added).

1 ““where the alleged disavowal of claim scope is ambiguous,”” it ““attaches and narrows the  
2 ordinary meaning of the claim congruent with the scope of the surrender”” where ““the patentee  
3 has unequivocally disavowed a certain meaning to obtain his patent.””<sup>3</sup> *Id.*

4 Before the PTAB, Dr. Samuels argued that the protrusions must be inflatable and that they  
5 “are unarguably identified by the circumferential ridges, such as ridges 25 in one embodiment  
6 clearly shown in Figure 2 . . . and are themselves in fluid communication with the inflatable  
7 chamber 27 of cuff 17.” Cohen Decl., Ex. 3 (Resp. at 5-6). He also argued that “the only  
8 supporting disclosure in the ‘575 patent is for a ridge which is itself part of the inflatable  
9 protrusion and contains fluid itself[;] [t]here simply is no support for the ridge being solid.”  
10 Cohen Decl., Ex. 3 (Resp. at 7). Ultimately, the PTAB adopted a construction in favor of Dr.  
11 Samuels, “determ[ing] that ‘inflatable protrusions’ are protrusions that are themselves inflatable,  
12 i.e., expandable by being filled with fluid,” as contended by Dr. Samuels. Cohen Decl., Ex. 4  
13 (PTAB Decision at 7, 10). Thus, based on the record, there is support for TriVascular’s argument  
14 that prosecution disclaimer is applicable here.

15 Accordingly, the Court construes the above-identified term as “a portion or portions of the  
16 outer surface of the inflatable cuff that protrude outward of the cuff and that are themselves  
17 inflatable, *i.e.*, expandable by being filled with fluid, including at least one ridge that goes around  
18 the cuff.”

19

---

20         <sup>3</sup> At least two judges in this District have noted that prosecution disclaimer has viability in  
21 IPR proceedings, even though an IPR is technically an adjudicative proceeding rather than an  
22 examination. *See, e.g., Evolutionary Intelligence, LLC v. Sprint Nextel Corp.*, No. C013094513,  
23 2014 U.S. Dist. LEXIS 139066, at \*20 (N.D. Cal. Sept. 26, 2014) (Whyte, J.) (“The IPR  
24 proceedings will also add to the ‘536 Patent’s prosecution history. Prosecution history is an  
25 important part of the intrinsic record relevant to claim construction. Statements made by  
26 Evolutionary Intelligence during the IPR could disclaim claim scope, aid the court in  
27 understanding the meaning of the terms, or otherwise affect the interpretation of key terms.”);  
28 *Pragmatus AV, LLC v. Yahoo! Inc.*, No. C-13-1176 EMC, 2014 U.S. Dist. LEXIS 65813, at \*14-  
15 (N.D. Cal. May 13, 2014) (“Under Federal Circuit law, comments made by a patent holder  
during inter partes reexamination proceedings can limit claim scope. The same should be true  
now that inter partes review, rather than inter partes reexamination, is in effect.”). And even if  
prosecution disclaimer is not an exact fit because an IPR is an adjudicative proceeding, it is  
analogous to judicial estoppel. *See Abbott Labs. v. Church & Dwight Co.*, No. 07 C 3428, 2008  
U.S. Dist. LEXIS 103635, at \*25 (N.D. Ill. Dec. 22, 2008) (“not[ing] that the doctrine of  
prosecution disclaimer is arguably analogous to the concept of judicial estoppel, which applies  
only if the party to be estopped was successful in the prior proceeding”).

1       D.     “a valve integral with the inflatable cuff for permitting entry of the inflation material from  
 2                   the means for injecting and thereafter sealing said cuff to prevent deflation”

4 <b>Dr. Samuels's Proposed</b> 5 <b>Construction</b>	4 <b>TriVascular's Proposed</b> 5 <b>Construction</b>	3 <b>Court's Construction</b>
<b>“a valve integral with the inflatable cuff for permitting entry of the inflation material from</b> <b>the means for injecting and thereafter sealing said cuff to prevent deflation”</b>		
8       Any structure that affects fluid 9       flow, formed or combined as a 10      unit with the cuff, and is 11      capable of not stopping 12      inflation material from 13      entering the cuff from the 14      means for injecting and 15      capable of stopping inflation 16      material from leaving the cuff 17      after the injection material has 18      entered the cuff to prevent 19      deflation.	8       A device built-in to the [cuff, 9       inflation port, or one of the 10      cuffs] that has a movable part 11      (such as leaflets) that open to 12      permit entry of the inflation 13      material and thereafter closes 14      to seal the cuff to prevent 15      deflation. This construction 16      does not cover inflation tubing 17      inserted into an inflation port 18      with an interference fit.	8       A valve, integral with the 9       inflatable cuff, that has a 10      movable part or parts (such as 11      leaflets) that open to permit 12      entry of the inflation material 13      and thereafter close to seal the 14      cuff to prevent deflation.
<b>“a valve”</b>		
21      Any structure that affects fluid 22      flow.	21      A device built-in to the [cuff, 22      inflation port, or one of the 23      cuffs] that has a movable part 24      (such as leaflets) that open to 25      permit entry of the inflation 26      material and thereafter closes 27      to seal the cuff to prevent 28      deflation. This construction	21      See above.

1	does not cover inflation tubing inserted into an inflation port with an interference fit.		
<b>“for permitting entry of the inflation material from the means for injecting and thereafter sealing said cuff to prevent deflation”</b>			
6 7 8 9 10 11 12 13 14 15 16	Capable of not stopping inflation material from entering the cuff from the means for injecting and capable of stopping inflation material from leaving the cuff after the injection material has entered to cuff to prevent deflation.	A device built-in to the [cuff, inflation port, or one of the cuffs] that has a movable part (such as leaflets) that open to permit entry of the inflation material and thereafter closes to seal the cuff to prevent deflation. This construction does not cover inflation tubing inserted into an inflation port with an interference fit.	See above.

17  
18 The terms can be found in, *e.g.*, claim 1(c).

19 As a preliminary matter, the Court takes note that, according to TriVascular, the phrase “a  
20 valve integral with the inflatable cuff for permitting entry of the inflation material from the means  
21 for injecting and thereafter sealing said cuff to prevent deflation” (*see, e.g.*, claim 1(c)) should be  
22 construed in its entirety. While Dr. Samuels has provided a construction for the entirety of the  
23 phrase, he also asserts that the Court should really just construe parts of that phase separately,  
24 namely (1) “a valve” and (2) “for permitting entry of the inflation material from the means for  
25 injecting and thereafter sealing said cuff to prevent deflation.” *See* Op. Br. at 16 (arguing that  
26 “Trivascular has impermissibly combined several terms and characterized them as one term”).  
27 The Court agrees with TriVascular that it makes more sense to construe the phrase in its entirety  
28 rather than in isolated portions, especially given the particular disputes between the parties

1 regarding the terms in the context of the entire phrase.

2 In evaluating the phrase “a valve integral with the inflatable cuff for permitting entry of the  
3 inflation material from the means for injecting and thereafter sealing said cuff to prevent  
4 deflation,” the Court begins by noting that there is some ambiguity. More specifically, is the valve  
5 at issue one that (1) permits entry of the inflation material and that (2) *actually* seals the cuff  
6 itself?<sup>4</sup> Or is the valve at issue one that (1) permits entry of the inflation material and that (2)  
7 *permits* sealing of the cuff (but does not do the actual sealing itself)?<sup>5</sup> The grammatical structure  
8 of the claim language better supports the first interpretation – *i.e.*, the valve permits entry and  
9 actually seals the cuff itself. Notably, there is parallel construction between the words  
10 “permitting” and “sealing.” *Compare* ‘851 patent, claim 6(b)<sup>6</sup> (claiming “[a]n apparatus for  
11 affixing an endoluminal device to the walls of tubular structures with in the body comprising  
12 [inter alia] a valve integral with said cuff to permit inflation and deflation”). Moreover, at the  
13 claim construction hearing, Dr. Samuels never argued in favor of the second interpretation;  
14 instead, he agreed that claim 1(c) requires that the valve both permit entry and do the sealing itself.

15 With this understanding, the main question becomes whether a valve that permits entry and  
16 thereafter seals is a valve that (1) has moveable parts that open and close, such as a mitre valve  
17 (TriVascular’s position), or that (2) can be such a valve but that can also be a valve without  
18 movable parts, such as a breakaway valve (Dr. Samuels’s position). The Court concludes that Dr.  
19 Samuels’s position is not persuasive.

20 First, it is notable that the phrase states the valve permits entry and “*thereafter* seal[s] . . .  
21 to prevent deflation.” ‘575 patent, claim 1(c) (emphasis added). The use of the word “thereafter”  
22 is important. It indicates that, *after* inflation, the valve seals to prevent deflation. A breakaway  
23 valve may seal and prevent deflation *during* the inflation process (*i.e.*, while the inflation tubing is

24  
25       <sup>4</sup> In other words, does the word “permitting” modify only the word “entry” and not the  
26 word “sealing”?

27       <sup>5</sup> In other words, does the word “permitting” modify both the word “entry” and the word  
28 “sealing”?

29       <sup>6</sup> The ‘851 patent is another patent owned by Dr. Samuels.

1 inserted), as Dr. Samuels argued at the hearing, but during and after are not the same thing. With  
2 a breakaway valve, after inflation, the inflation tubing is removed, *see* '575 patent, col. 4:24-27  
3 (stating that, “[r]eferring to FIG. 4b, once cuff 17 has been inflated (or deflated) to the desired  
4 level, a sharp tug on inflating tubing 61 in a direction away from inflation port 39 causes  
5 circumferential notch 65 [part of the inflation tubing] and circumferential rim 55 [part of the  
6 breakaway valve] to disengage”), and there is nothing in the '575 patent to indicate that the  
7 breakaway valve itself seals, as opposed to, *e.g.*, a hardening agent in the inflation material. *See*  
8 '575 patent, col. 4:34-43 (“The inflation material could be a saline-based fluid or a material that  
9 contains a photo-activated or heat-activated hardening agent or any hardening agent that hardens  
10 over time. . . . After cuff 17 has been installed and inflated, the material 73 hardens over time to  
11 permanently affix stent 5 within the tubular structure of the body via circumferential ridges.”).

12 Second, although it is possible for the inflation material to seal itself allowing the  
13 breakaway valve to be removed, the '575 specification clearly contemplates that the inflation  
14 material can be a fluid *without* any hardening agent. *See* '575 patent, col. 4:34-37 (“The inflation  
15 material could be a *saline-based fluid* or a material that contains a photo-activated or heat-  
16 activated hardening agent or any hardening agent that hardens over time.”) (emphasis added).  
17 That being the case, claim 1 of the '575 patent requires a valve that permits entry and thereafter  
18 seals either with *or* without the use of any hardening agent in the inflation material. Indeed, this is  
19 underscored by dependent claim 7 which requires inflation material *with* a hardening agent. *See*  
20 '575 patent, claim 7 (covering “[t]he inflatable intraluminal stent of claim 1 wherein the inflation  
21 material includes a hardening agent”). Dr. Samuels has failed to explain how a breakaway valve  
22 could do the sealing (after inflation is completed) in a case where the fluid (inflation material)  
23 does not contain any hardening agent without, *e.g.*, a mitre valve. While, at the hearing, Dr.  
24 Samuels asserted that there could be some other kind of valve without movable parts that could do  
25 sealing, even without any hardening agent – *e.g.*, if the valve had a physical structure with a  
26 decreasing orifice size, such that, with the right pressure, inflation material could be forced in but  
27 would not thereafter “leak out” – he failed to offer any evidence showing that this was in fact  
28 possible. Furthermore, nothing in the patent specifications suggests such a valve. *See* note 2,

1       *supra*.

2           Third, as TriVascular points out, in multiple places in the specification, there are only  
 3           references to a valve that seals being a valve that closes (such as a mitre valve) – which would  
 4           require movable parts associated with the valve. *See, e.g.*, ‘575 patent, col. 4:29-32 (stating that,  
 5           “[u]pon withdrawal of the mating end **63** of inflation tubing **61**, . . . opposing leaflets **51** and **53** of  
 6           mitre valve **45** close to seal the inflated cuff **17**”); ‘575 patent, col. 6:26-29 (stating that, “[a]s the  
 7           catheter is pulled away, the breakaway valve within port **123** releases inflation tubing **115** and the  
 8           mitre valve [which has leaflets that open and close] seals port **123** in a manner similar to the one  
 9           illustrated in FIG. **4b**”); *see also* note 2, *supra*. This is consistent with the position that Dr.  
 10           Samuels took before the PTAB in the IPR proceeding. *See, e.g.*, Cohen Decl., Ex. 1 (Prelim.  
 11           Resp. at 2) (stating that “[s]tent 5 also includes a means for injecting or inflating with an inflation  
 12           material and a valve 45 [*i.e.*, a mitre valve<sup>7</sup>] for permitting entry of the inflation material into cuff  
 13           17 and thereafter sealing cuff 17 to prevent deflation”); Cohen Decl., Ex. 3 (Resp. at 4) (stating  
 14           that “[s]tent 5 also includes a valve 45 [*i.e.*, a mitre valve] for permitting entry of the inflation  
 15           material into cuff 17, allowing deflation, and finally sealing cuff 17 to prevent deflation”).

16           Finally, dependent claims 8 and 9 are not sufficient to establish that a valve that seals after  
 17           inflation can be one without movable parts. For example, claim 8 covers “[t]he inflatable  
 18           intraluminal stent of claim **1** wherein the valve is a mitre valve.” ‘575 patent, claim 8. But simply  
 19           because a mitre valve is called out in claim 8 does not thereby mean that a breakaway valve (or  
 20           other valve without movable parts) is a valve that seals thereafter, as required in claim 1. A mitre  
 21           valve is one specific kind of valve with movable parts; Dr. Samuels has not demonstrated that  
 22           there are not others. *See also Phillips*, 415 F.3d at 1315 (noting that “the presence of a dependent  
 23           claim that adds a particular limitation gives rise to a presumption that the limitation in question is  
 24           not present in the independent claim”). Claim 9 covers “[t]he inflatable intraluminal stent of claim  
 25           **1** wherein the valve is of a breakaway design to permit separation from the means for injecting.”  
 26           ‘575 patent, claim 9. But claim 9 need not be interpreted to mean that a breakaway valve is

---

27  
 28           <sup>7</sup> *See* ‘575 patent, col. 4:12-14 (stating that “[m]itre valve **45** features opposing leaflets **51**  
          and **53** which are constructed of a non-elastomeric, biologically inert material”).

1 therefore a valve that seals after inflation, as required by claim 1. It does not preclude a  
 2 breakaway valve in addition to, *e.g.*, a mitre valve as shown in the drawings. In other words,  
 3 claim 9 can be interpreted to mean that the valve that actually seals in claim 1 (such as a mitre  
 4 valve) is given an additional feature – *i.e.*, a breakaway design. In fact, that interpretation makes  
 5 more sense given the language in claim 9 that the breakaway design’s purpose is “to permit  
 6 separation from the means for injecting,” and therefore not to seal.

7 Accordingly, the Court construes the phrase “a valve integral with the inflatable cuff for  
 8 permitting entry of the inflation material from the means for injecting and thereafter sealing said  
 9 cuff to prevent deflation” as follows: “a valve, integral with the inflatable cuff, that has a movable  
 10 part or parts (such as leaflets) that open to permit entry of the inflation material and thereafter  
 11 close to seal the cuff to prevent deflation.” The Court need not add limitations beyond that, as  
 12 suggested by TriVascular, as a valve involving inflation tubing inserted into an inflation port with  
 13 an interference fit does not have a movable part or parts. Likewise, the Court need not add  
 14 language regarding capability, as proposed by Dr. Samuels, because it is confusing and  
 15 unnecessary given the construction above.

16 E. “inflatable and deflatable cuff of generally hollow cylindrical continuation [sic  
 17 configuration]”<sup>8</sup>

19 Dr. Samuels’s Proposed 20 Construction	21 TriVascular’s Proposed 22 Construction	23 Court’s Construction
24 Cuff of generally hollow 25 configuration.	26 A band-like structure that has 27 an inner surface and outer 28 surface creating an inflatable chamber that may be inflated by filling the chamber with fluid or deflated by allowing	29 A cuff, of generally hollow 30 configuration, that has an inner surface and an outer 31 surface and an inflatable and 32 deflatable chamber in between 33 the surfaces.

27  
 28 <sup>8</sup> The Court **GRANTS** TriVascular’s administrative motion to file notice of supplemental  
 citation. *See* Docket No. 90.

1	the fluid to leave in ordinary	
2	use.	

3

4        This term can be found in, *e.g.*, claim 1(a).

5        As a preliminary matter, the Court takes note that Dr. Samuels has asked for construction  
 6 of a slightly narrower term – *i.e.*, “cuff of generally hollow cylindrical continuation [sic  
 7 configuration].” However, it is proper to construe the broader term, as advocated by TriVascular,  
 8 particularly given Dr. Samuel’s objection to TriVascular’s proffered construction. *See, e.g.*, Reply  
 9 at 12 (arguing that “[t]here is no support for adding the additional language of an inflatable  
 10 chamber, nor is it needed”).

11       The crux of the dispute here (which was not fully fleshed out until the hearing) is whether  
 12 a cuff has an inflatable chamber between the cuff’s inner surface and outer surface. *See, e.g.*, ‘575  
 13 patent, Fig. 2 (inflatable chamber at **27**); ‘575 patent, col. 3:54-56 (“As illustrated in FIG. 2,  
 14 circumferential ridges **25** are in fluid communication with the inflatable chamber **27** of cuff **17**.”).  
 15 TriVascular argues that a cuff does; Dr. Samuels argues that a cuff can have an inflatable chamber  
 16 but such is not required; that is, it is permissible to have only the inflatable protrusion(s) inflated.

17       Dr. Samuels’s position is without merit. The cuff is expressly described as “inflatable and  
 18 deflatable” in the term. To be inflatable, there must be a chamber within the cuff that can be filled  
 19 with inflation material. If the ‘575 patent was intended to cover only an expandable cuff, then Dr.  
 20 Samuels could easily have used the term “expandable” or a word akin thereto. Instead, he chose  
 21 the word “inflatable,” a word that is also used in the patent term “inflatable protrusions.” Dr.  
 22 Samuels has failed to explain why “inflatable” should have one meaning when used in conjunction  
 23 with the cuff and a different meaning when used in conjunction with the protrusions.<sup>9</sup>

24

---

25       <sup>9</sup> In a supplemental brief, Dr. Samuels argued that “inflatable cuff” may still refer to a cuff  
 26 with only the inflatable protrusion(s) inflated because the inflatable protrusion(s) is/are *part* of the  
 27 cuff. *See* Docket No. 91 (Dr. Samuels’s Supp. Br. at 2) (arguing that “the inflatable cuff of claim  
 28 1 may be inflated by inflation of just the inflatable protrusion(s) which is/are part of the ‘cuff’ as  
 claimed”). But this argument is not persuasive because the cuff is the entire structure; thus, an  
 “inflatable cuff” must mean that the entire structure is inflated. Notably, nowhere in the  
 specification is it suggested that an inflatable cuff can be a cuff with only a portion of it inflated.  
*See* note 2, *supra*. Moreover, given that the claim allows for only one circumferential ridge, Dr.

1       At the hearing, Dr. Samuels pointed to independent claims 14 and 23 as supportive of his  
2 position, *see generally Tandon Corp. v. U.S. Int'l Trade Comm'n*, 831 F.2d 1017, 1023 (Fed. Cir.  
3 1987) (stating that “[t]here is presumed to be a difference in meaning and scope when different  
4 words or phrases are used in separate claims” and that, “[t]o the extent that the absence of such  
5 difference in meaning and scope would make a claim superfluous, the doctrine of claim  
6 differentiation states the presumption that the difference between claims is significant”), but the  
7 Court is unpersuaded. Admittedly, claim 14 does refer to “a cuff having a collapsible lumen, an  
8 inner surface and a friction-enhancing outer surface with an inflatable and deflatable chamber  
9 disposed there between.” ‘575 patent, claim 14. But simply because the cuff, as described in  
10 claim 14, refers to an inflatable and deflatable chamber, does not mean that the cuff, as described  
11 in other claims (e.g., claim 1) does not have such a chamber. “The doctrine of claim  
12 differentiation is at its strongest . . . ‘where the limitation that is sought be “read into” an  
13 independent claim already appears in a dependent claim.’” *InterDigital Communs., LLC v. ITC*,  
14 690 F.3d 1318, 1324 (Fed. Cir. 2012). But here, claims 14 and 23 are not dependent claims; they,  
15 like claim 1, are independent claims. Notably, the Federal Circuit has stated that it has

16       been cautious in assessing the force of claim differentiation in  
17 particular settings, recognizing that patentees often use different  
18 language to capture the same invention, discounting it where it is  
19 invoked based on independent claims rather than the relation of an  
independent and dependent claim, and not permitting it to override  
the strong evidence of meaning supplied by the specification.  
20 *Atlas IP, LLC v. Medtronic, Inc.*, No. 2015-1071, 2015 U.S. App. LEXIS 18819, at \*16 (Fed. Cir.  
21 Oct. 29, 2015). The Court also notes that “[a] further reason for not applying the doctrine of  
22 claim differentiation in this case is that the [claims at issue] are not otherwise identical.” *Andersen  
23 Corp. v. Fiber Composites, LLC*, 474 F.3d 1361, 1370 (Fed. Cir. 2007) (noting that “there are  
24 numerous other differences varying the scope of the claimed subject matter”). Claim 1, for  
25 example, is targeted to an “inflatable intraluminal stent” specifically whereas claim 14 is directed  
26 more broadly to an “apparatus for disposition within the lumen of a tubular structure.”

27  
28 Samuels’s construction makes little sense because, if only that ridge (and not the cuff) is inflated,  
the cuff would consist of simple ring and not a cylinder.

1           Accordingly, the Court construes the phrase ““inflatable and deflatable cuff of generally  
 2 hollow cylindrical continuation [sic configuration]” as “a cuff, of generally hollow configuration,  
 3 that has an inner surface and an outer surface and an inflatable and deflatable chamber in between  
 4 the surfaces.” The Court declines to provide a specific definition for the term “cuff” (*e.g.*, as a  
 5 band-like structure) as the term is understandable to a lay person.

6           F.       “affixing the cuff with [sic within] the lumen of the tubular structure without penetration  
 7 of the tubular structure”

9 <b>Dr. Samuels’s Proposed</b> 10 <b>Construction</b>	9 <b>TriVascular’s Proposed</b> 10 <b>Construction</b>	9 <b>Court’s Construction</b>
11           Causing the cuff to resist 12           movement within the lumen of 13           the tubular structure without 14           penetration of the tubular 15           structure.	11           The cuff is fixedly secured to 12           the interior of the tubular 13           structure to hold it in place 14           without penetration of the 15           tubular structure.	Plain and ordinary meaning.

16           This term can be found in, *e.g.*, claim 14(b).

17           The Court sees no need to define the claim term, not only because the word “affixing” is  
 18 not a term beyond a lay person’s comprehension but also because there is no real difference  
 19 between the parties’ proposed constructions. This is substantiated by the specification of the  
 20 patent which describes “affixing” in the following contexts:

- 21           • “If the initial placement of the stent within the tubular structure is not optimal, it may be  
 22           deflated, repositioned to the optimal position and reinflated so as to again be affixed to the  
 23           tubular walls via its outer surface.” ‘575 patent, col. 2:39-42.
- 24           • “As shown in FIG. 1, outer surface **23** features a number of inflatable ridges **25** disposed  
 25           about its circumference. While inflatable ridges are shown in the FIGS., any friction-  
 26           enhancing outer surface, that would secure the inflated stent to the interior wall of a tubular  
 27           structure without penetrating it, could be used.” ‘575 patent, col. 3:33-37.

1     • “As illustrated in FIG. 3, the outer surface **30** of the cuff is made coarse by a combination  
2         of raised portions **31** and lowered portions **33**. These surface features allow the inflated  
3         stent to grip the interior walls of a tubular structure with a force that is sufficient to prevent  
4         its migration.” ‘575 patent, col. 3:62-66.

5     • “In addition, it may be desirable in some applications to provide the cuff with an outer  
6         surface that promotes tissue ingrowth. This would allow the stent to become more  
7         integrated, and thus more firmly affixed, within the tubular structure as time progresses.”  
8         ‘575 patent, col. 4:1-5.

9     • “As shown in FIGS. 5c and 6c, stent **89** is inflated so that the size of the lumen of stent **89**  
10         approximates the lumen size of the original, unconstructed blood vessel. By doing so,  
11         constricted portion **83** is compressed between blood vessel wall **85** and stent **89**, the latter  
12         of which is fixed in place by way of protruding ridges **91**.” ‘575 patent, col. 4:59-64.

13     • “A unique feature of the present invention is its capability of being optimally positioned  
14         within a tubular structure in the body (in this case, a blood vessel) without causing damage  
15         to the surrounding tissue. Specifically, after stent **89** has been inflated so that ridges **91**  
16         affix the stent to the tubular walls without penetration, the position of the stent is examined  
17         fluoroscopically to determine if it is optimal. If not, stent **89** may be deflated, repositioned  
18         and then reinflated.” ‘575 patent, col. 4:66-5:7.

19     • “The stent-graft is secured to the vessel walls via ridges **96** so that blood passes through  
20         graft **92**.” ‘575 patent, col. 5:32-33.

21         Dr. Samuels’s position, as articulated during the IPR proceedings, does not indicate  
22         anything different. *See* Cohen Decl., Ex. 11 (Clark Decl. ¶ 5(a), 8) (referring to the ridges  
23         “holding the stent in place” and “maintain[ing] a desired position”); Cohen Decl., Ex. 12 (Samuels  
24         Decl. ¶ 4(b)) (noting that the stent can be “held fixed in a desired location”).

25         Moreover, claim 14(b) itself reads in full as follows: “said friction-enhancing outer surface  
26         featuring inflatable protrusion(s) including at least one circumferential ridge disposed about the  
27         inflatable cuff and affixing the cuff with the lumen of the tubular structure without penetration of  
28         the tubular structure when the cuff is fully inflated *so that movement of the cuff in a longitudinal*

1        *direction with respect to the tubular structure is prevented.”* ‘575 patent, claim 14(b) (emphasis  
2        added). The meaning of “affix” is clear, particularly when viewed in the context of the italicized  
3        language. Given the context of the full claim limitation, there is no need to reiterate the point that  
4        movement is resisted or that the cuff is held in place.

5        G.        “said friction-enhancing outer surface engaging the interior of the tubular structure without  
6        penetration to prevent the cuff from moving”

8 <b>Dr. Samuels’s Proposed</b> 9 <b>Construction</b>	10 <b>TriVascular’s Proposed</b> 11 <b>Construction</b>	12 <b>Court’s Construction</b>
13        Outer surface capable of 14        engaging the interior of the 15        tubular structure without 16        penetration and capable of 17        preventing the cuff from 18        moving and enhancing 19        friction.	20        Said friction enhancing outer 21        surface gripping the interior of 22        the tubular structure with 23        sufficient force to fixedly 24        secure the cuff to keep/hold it 25        in place without penetration of 26        the tubular structure.	27        Plain and ordinary meaning.

28        This term can be found in, *e.g.*, claim 1(a).

29        Basically, the dispute here is similar to the one immediately above, and the Court therefore  
30        rests on plain and ordinary meaning.

### 31        **III. CONCLUSION**

32        For the foregoing reasons, the Court adopts the above constructions for the claim terms at  
33        issue.

34        **IT IS SO ORDERED.**

35        Dated: November 12, 2015



36        **EDWARD M. CHEN**  
37        United States District Judge